Jul, 2021

New findings from the ODYSSEY trial confirm superiority of dolutegravir-based ART in younger children – A story by WHO

Tags: , ,

WHO welcomes new findings presented today at International Pediatric HIV Workshop on the superiority of dolutegravir (DTG)-based regimens in young children. Children living with HIV continue to be left behind by the global AIDS response. In 2020, only 54% of the 1.7 million children living with HIV received antiretroviral therapy in 2020 compared to 74% among adults living with HIV. Among the focus countries, only 40% of children living with HIV (or 74% of children receiving antiretroviral therapy) achieved viral suppression in 2020. The ODYSSEY trial, a multi-country randomised trial […]



Mar, 2021

ODYSSEY team at Radboud receives the RIHS Societal Award 2020


As the world continues to raise its voice towards improving HIV treatment for children, the contributions made by the ODYSSEY trial have not gone unnoticed and as a result, has earned researchers the Radboud Institute for Health Sciences Societal Impact Award. “We are very proud to have received the Radboud Institute for Health Sciences Societal Impact Award 2020 for our work on a simplified dolutegravir dosing schedule for children of at least 20kg. This study, within the Odyssey trial, makes dolutegravir treatment possible for children living with HIV in Africa. […]



Mar, 2021

ODYSSEY trial finds new drug is better for treating children living with HIV

Tags: , , ,

The anti-HIV drug Dolutegravir improves outcomes for children with HIV infection when given in a 3-drug combination. These results come from the ODYSSEY trial which was presented yesterday at the Conference on Retroviruses and Opportunistic Infections. Dolutegravir has a number of potential advantages, including: Few drug-to-drug interactions, making it easier to use when treating people who need treatment for other conditions such as tuberculosis High potency at a low milligram dose, meaning tablets can be small High genetic barrier to resistance Low cost Trials of dolutegravir in combination treatments in […]



Jan, 2021

EU grants Marketing Authorisation to first-ever dispersible-tablet dolutegravir

Tags: , ,

On 12 January 2021, the European Medicine Agency approved the use of dolutegravir 5mg dispersible tablets for treating HIV in young children living in Europe. This decision was based, in part, on data from our ODYSSEY trial, which we are conducting in close collaboration with the MRC CTU at the University College London. The EMA also authorised updating dosing recommendations for dolutegravir film-coated tablets (10mg, 25mg and 50mg) for children six years and older and weighing at least 14kg, bringing these in line with the World Health Organization weight bands. […]



Nov, 2020

European Medicines Agency approves use of Dolutegravir 5 mg dispersible tablet for younger children living with HIV

Tags: ,

On November 12th, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending marketing authorisation for dolutegravir 5mg dispersible tablets for young children living with HIV. This decision was based, in part, on data from the ODYSSEY trial. These small tablets can now be used in combination with other medicines for treating children living with HIV who are aged at least four weeks and weigh at least 3kg. CHMP’s positive opinion also supported the updated dosing recommendations for dolutegravir film-coated […]


We would like to update you on our recent activities